AlphAIalphai — Financial news for AI agents
BenzingaOCT 173 min read$WHWK

Whitehawk Therapeutics Dips Over 8% In After-Hours Trading Despite New Tempus AI Partnership - Whitehawk Therapeutics (NASDAQ:WHWK)

Whitehawk Therapeutics Inc. ( NASDAQ:WHWK ) dropped 8.81% in after-hours trading Thursday, closing at $2.38, after announcing a multi-year collaboration with Tempus AI. Check out the current price of WHWK stock here. WHWK closed Thursday at $2.61, up 23.70% on the day, according to Benzinga ...

Original reporting
Benzinga · Mohd Haider
Published Oct 17, 2025, 4:44 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 17, 2025, 5:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Whitehawk Therapeutics Dips Over 8% In After-Hours Trading Despite New Tempus AI Partnership - Whitehawk Therapeutics (NASDAQ:WHWK) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$WHWKNeutralLow
01

Why it matters

The partnership initially boosted investor optimism, but profit-taking and skepticism led to an after-hours decline, reflecting mixed market sentiment.

02

Market read

The news has short-term relevance for WHWK and related biotech stocks, with limited broader market impact.

03

What to watch

Broader market conditions, sector rotation, and upcoming earnings reports could influence stock performance beyond news headlines.

Timing: Immediate to short-term

Background

Whitehawk Therapeutics announced a multi-year collaboration with Tempus AI, aiming to leverage AI for biotech advancements.

Company-level read

Ticker impact

$WHWKNeutralMedium confidence
Context

High relevance due to recent price movement and partnership news.

Expected impact

Short-term volatility with potential for a rebound if partnership prospects are realized; medium-term outlook remains uncertain.

Evidence & confidence

The initial positive reaction was driven by partnership news, but the subsequent decline suggests profit-taking or skepticism. Technical levels and broader market conditions should be monitored for clearer signals.

$TEMBullishMedium confidence
Context

Moderate relevance; sentiment indicates a somewhat bullish outlook, but limited direct impact from the news on TEM's stock.

Expected impact

Minimal impact expected; possible slight positive bias if partnership benefits are perceived.

Evidence & confidence

The partnership may indirectly benefit TEM, but current data does not suggest a significant immediate price movement.

Market effects

Sector

Potential positive sentiment for biotech and pharmaceutical sectors due to AI collaborations.

Regional

Limited; primarily affects US-based biotech stocks.

Global

Low; specific to US biotech sector and individual companies.

Counterpoint

What could challenge this read

The decline may be a temporary profit-taking move; the partnership could still lead to positive long-term developments.

Key entities

  • Company
    Whitehawk Therapeutics

    Biotech company focusing on innovative therapies.

  • Partnership Entity
    Tempus AI

    AI technology provider collaborating with Whitehawk.

Read at source← All news

Related articles

AUG 7
$TEMMed

Why Is Tempus AI Stock Surging on Friday? - Tempus AI (NASDAQ:TEM)

Tempus AI Inc. (NASDAQ:TEM) shares rose about 11% on Friday, outperforming the Nasdaq and the Healthcare sector, amid an AI-healthcare sector rally. The move followed strong peer results, including Doximity’s fiscal Q1 revenue of $156.6 million, and a strategic collaboration with CellCarta adding Tempus to its CDx lab network. TEM traded near $50.95.

benzinga.com4 min
AUG 6
$WHWKMed

Whitehawk Therapeutics, Inc. (WHWK): Results of Operations and Financial Condition

Whitehawk Therapeutics, Inc. (WHWK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 whwk-ex99_1.htm EX-99.1 EX-99.1 PRESS RELEASE Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026 Cash, cas

SEC EDGAR 8-K4 min
AUG 3
$TEMMed

BTIG cuts Tempus AI stock price target to $70 on model update

BTIG cut its Tempus AI (NASDAQ:TEM) price target to $70 from $80 while keeping a Buy rating after the company’s Q2 2026 earnings call. Tempus AI reported 22% YoY revenue growth, raised 2026 revenue guidance to 25% to 26%, and posted $382.5M revenue with an adjusted EPS loss of $0.04. BTIG cited Tempus’s $1.5B Personalis deal with a $46 stock-price termination trigger.

investing.com3 min
JUL 31
$TEMMedAI 8/10

Dear Tempus AI Stock Fans, Mark Your Calendars for July 30

Tempus AI (NASDAQ: TEM) agreed to acquire Personalis (PSNL) for $16.25 per share in stock, valuing the deal at about $1.5 billion enterprise value net of Tempus’ existing stake, with closing expected late 2026 or early 2027. Tempus expects integration to expand MRD capabilities. After the July 20 announcement, TEM fell 7.74% intraday. In Q1, revenue rose 36.1% to $348.12M. Needham reiterated Buy at $75; consensus target is $66.75.

yahoo.com5 min
JUL 31
$TEMMedAI 8/10

Tempus AI Raises FY2026 Sales Guidance to $1.595B-$1.605B

Tempus AI (NASDAQ: TEM) has raised its full-year 2026 sales guidance, signaling robust demand for its artificial intelligence-driven healthcare solutions. The company updated its revenue outlook to a range of $1.595 billion to $1.605 billion, an increase from the previous guidance of $1.590 billion to $1.600 billion.

scanx.trade5 min
JUL 30
$TEMMedAI 8/10

Tempus AI Q2 Results: Revenue rises 22% YoY, stock slides

Tempus AI (NASDAQ: TEM) reported second-quarter revenue of $382.5 million, rising 22% year-over-year and surpassing Street consensus estimates of $379.7 million. Despite the top-line beat and a narrower-than-expected loss per share of four cents versus an estimated 14 cents loss, shares declined 2.4% in after-hours trading to $43.25.

scanx.trade5 min